Microbiome Company Myota Raises $4.5 Million Series A

Myota, a gut-microbiome company that has developed a patented range of prebiotic fiber blends, has closed a $4.5 million Series A led by PeakBridge. The capital will fund a dedicated B2B sales operation in the U.S. and Europe, support and scale the company’s D2C business, and extend clinical research.

Myota’s ingredient blends are built on proprietary research designed to maximize short-chain fatty acid production, regardless of microbiome composition, while minimizing gastrointestinal discomfort. This creates an ingredient platform that can demonstrate efficacy in clinical trials and be used at meaningful doses in everyday food and drink products.

“We can measure how an individual’s gut bacteria ferment different fibers, and we use that to build blends that produce short-chain fatty acids reliably across very different microbiomes,” said Thomas Gurry, co-founder and chief scientific officer of Myota. “Our randomized controlled trials have shown improvements in insulin sensitivity, blood sugar control, inflammation, and mood, including stress and anxiety. That evidence base is what separates a functional ingredient from a marketing claim.”

In B2B, Myota launched a global partnership with Joe & The Juice last year, signed supply agreements with a coffee-alternative brand, and has product development underway with household names in dairy, bakery, and functional beverages.

Distribution agreements with Suannutra and Denava now cover the U.S., U.K., and E.U. The direct-to-consumer business has surpassed 60,000 customers, the company said.

“Fiber is one of the most powerful and overlooked levers for human health, and for years the products on shelves haven’t done it justice,” said Kat Stennett, co-founder and CEO of Myota. “What’s been missing is fiber that works across real, varied microbiomes and stands up to clinical scrutiny. That is what we’ve built, and it’s why companies across F&B, food service, and wellness are coming to us to put genuine, claimable benefits into their products. This round lets us meet that demand at scale.”

“Most gut-health products are a marketing story built on one or two commodity fibers,” said Yoni Glickman, managing partner at PeakBridge. “Myota built and patented the science first and then validated the outcomes in clinical trials. We saw fiber becoming a pillar of modern nutrition five years ago, backed Myota early, and we’re proud to continue supporting their excellent team now.”